This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
All You Need to Know About Illumina (ILMN) Rating Upgrade to Buy
by Zacks Equity Research
Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays
by Zacks Equity Research
Illumina (ILMN) derives benefits from the cascading effect of the ACOG guidance on increasing coverage of NIPT for all pregnancies.
Stock Market News for Jun 11, 2021
by Zacks Equity Research
Benchmarks closed in the green as investors shrugged off inflation report in agreement with the Fed's argument that jump in prices is temporary as demand exceed supply on account of the economy's recovery from the pandemic
The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen
Top Research Reports for Intel, NextEra Energy & PetroChina
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), NextEra Energy (NEE), and PetroChina Company (PTR).
LHC Group (LHCG) Expands Hospice Presence with New Buyout
by Zacks Equity Research
LHC Group (LHCG) agrees to purchase Heart of Hospice to extend its hospice footprint in five states.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Here's Why You Should Retain PRA Health (PRAH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.
Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies
by Zacks Equity Research
Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.
Illumina (ILMN) Expands NIPT Offering With New Collaboration
by Zacks Equity Research
Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
by Zacks Equity Research
BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.
Change Healthcare (CHNG) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance in the Network Solutions segment.
Illumina (ILMN) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NextGen (NXGN) Announces Positive Telehealth Survey Results
by Zacks Equity Research
NextGen's (NXGN) recent survey indicates growing preference for telehealth services.
QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm
by Zacks Equity Research
QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.
Allscripts (MDRX), Lash Group Team Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration to streamline specialty medication management for medical clinics and practices across the nation.
Exact Sciences (EXAS) Reveals Promising Data on Cologuard
by Zacks Equity Research
Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.
PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study
by Zacks Equity Research
PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.